What lessons can be learned from γδ T cell-based cancer immunotherapy trials?

Questionable Relevance of    T Lymphocytes in Renal Cell Carcinoma

(2014) B. A. Inman et al.   JOURNAL OF IMMUNOLOGY

CD70 expression patterns in renal cell carcinoma

(2012) Lucia B. Jilaveanu et al.   HUMAN PATHOLOGY

Human V 9V 2 T Cells Specifically Recognize and Kill Acute Myeloid Leukemic Blasts

(2012) J. Gertner-Dardenne et al.   JOURNAL OF IMMUNOLOGY

Tumor-promoting Versus Tumor-antagonizing Roles of γδ T Cells in Cancer Immunotherapy

(2012) Volker Kunzmann et al.   JOURNAL OF IMMUNOTHERAPY

Harnessing γδ T cells in anticancer immunotherapy

(2012) Dalil Hannani et al.   TRENDS IN IMMUNOLOGY

Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours

(2011) A J Nicol et al.   BRITISH JOURNAL OF CANCER

Combined Genetic Inactivation of β2-Microglobulin and CD58 Reveals Frequent Escape from Immune Recognition in Diffuse Large B Cell Lymphoma

(2011) Madhavi Challa-Malladi et al.   CANCER CELL

Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma

(2011) Joshua M. Lang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

How tumors might withstand γδ T-cell attack

(2011) Aude-Hélène Capietto et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Interindividual Variability of Response to Rituximab: From Biological Origins to Individualized Therapies

(2011) G. Cartron et al.   CLINICAL CANCER RESEARCH

The gene expression profile of phosphoantigen-specific humanγδT lymphocytes is a blend of αβ T-cell and NK-cell signatures

(2011) Fréderic Pont et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Stimulated    T Cells Increase the In Vivo Efficacy of Trastuzumab in HER-2+ Breast Cancer

(2011) A.-H. Capietto et al.   JOURNAL OF IMMUNOLOGY

Adjuvant zoledronic acid for breast cancer: mechanism of action?

(2011) Volker Kunzmann et al.   LANCET ONCOLOGY

Immune parameters affecting the efficacy of chemotherapeutic regimens

(2011) Laurence Zitvogel et al.   Nature Reviews Clinical Oncology

PGE2 inhibits natural killer and γδ T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling

(2010) Ludovic Martinet et al.   BIOCHEMICAL PHARMACOLOGY

Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vγ9Vδ2 T lymphocyte agonist in patients with solid tumors

(2010) Jaafar Bennouna et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Optimizing Tumor-Reactive γδT Cells for Antibody-Based Cancer Immunotherapy

(2010) S. Meraviglia et al.   CURRENT MOLECULAR MEDICINE

Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors

(2010) Atsutaka Noguchi et al.   CYTOTHERAPY

A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous γδ T cells☆☆☆

(2010) Jun Nakajima et al.   EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

Phosphoantigens Overcome Human TCRV 9+    Cell Immunosuppression by TGF- : Relevance for Cancer Immunotherapy

(2010) A.-H. Capietto et al.   JOURNAL OF IMMUNOLOGY

V 9V 2 T Lymphocytes Efficiently Recognize and Kill Zoledronate-Sensitized, Imatinib-Sensitive, and Imatinib-Resistant Chronic Myelogenous Leukemia Cells

(2010) M. D'Asaro et al.   JOURNAL OF IMMUNOLOGY

Zoledronate Stimulates γδ T Cells in Prostate Cancer Patients

(2010) Michio Naoe et al.   ONCOLOGY RESEARCH

Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies

(2009) J. Gertner-Dardenne et al.   BLOOD

Antitumor Activity of    T Cells Reactive against Cytomegalovirus-Infected Cells in a Mouse Xenograft Tumor Model

(2009) C. Devaud et al.   CANCER RESEARCH

A regulatory cross-talk between Vγ9Vδ2 T lymphocytes and mesenchymal stem cells

(2009) Ludovic Martinet et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Clinical and immunological evaluation of zoledronate-activated Vγ9γδ T-cell-based immunotherapy for patients with multiple myeloma

(2009) Yu Abe et al.   EXPERIMENTAL HEMATOLOGY

γδ T cells as immune effectors against high-grade gliomas

(2009) Lawrence S. Lamb   IMMUNOLOGIC RESEARCH

Pitfalls on the roadmap to γδ T cell-based cancer immunotherapies

(2009) Ludovic Martinet et al.   IMMUNOLOGY LETTERS

Large scale expansion of Vγ9Vδ2 T lymphocytes from human peripheral blood mononuclear cells after a positive selection using MACS “TCR γ/δ + T cell isolation kit”

(2009) Samuel Salot et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Cutting Edge: TGF- 1 and IL-15 Induce FOXP3+    Regulatory T Cells in the Presence of Antigen Stimulation

(2009) R. Casetti et al.   JOURNAL OF IMMUNOLOGY

Chemokine Receptors Expression and Migration Potential of Tumor-infiltrating and Peripheral-expanded Vγ9Vδ2 T Cells From Renal Cell Carcinoma Patients

(2009) Emilie Viey et al.   JOURNAL OF IMMUNOTHERAPY

Characterization and immunotherapeutic potential of γδ T-cells in patients with glioblastoma

(2009) Nichole L. Bryant et al.   NEURO-ONCOLOGY

Phosphoantigen-activated V 2V 2 T cells antagonize IL-2-induced CD4+CD25+Foxp3+ T regulatory cells in mycobacterial infection

(2008) G. Gong et al.   BLOOD

Intravesical administration of γδ T cells successfully prevents the growth of bladder cancer in the murine model

(2008) Takeshi Yuasa et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma

(2008) Jaafar Bennouna et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Zoledronate facilitates large-scale ex vivo expansion of functional γδ T cells from cancer patients for use in adoptive immunotherapy*

(2008) M. Kondo et al.   CYTOTHERAPY

Inhibition of phosphoantigen-mediated γδ T-cell proliferation by CD4+ CD25+ FoxP3+regulatory T cells

(2008) Volker Kunzmann et al.   IMMUNOLOGY